Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model.

Ozanne EM, Braithwaite D, Sepucha K, Moore D, Esserman L, Belkora J.

J Clin Oncol. 2009 Jan 10;27(2):214-9. doi: 10.1200/JCO.2008.17.3914. Epub 2008 Dec 1.

PMID:
19047286
2.
4.

Population-based validation of the prognostic model ADJUVANT! for early breast cancer.

Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, Davis GJ, Chia SK, Gelmon KA.

J Clin Oncol. 2005 Apr 20;23(12):2716-25.

PMID:
15837986
5.

A population-based study on variations in the use of adjuvant systemic therapy on postmenopausal patients with early stage breast cancer.

Nagel G, Röhrig B, Hoyer H, Wedding U, Katenkamp D.

J Cancer Res Clin Oncol. 2003 Mar;129(3):183-91. Epub 2003 Apr 23.

PMID:
12709795
6.

Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity?

Keating NL, Landrum MB, Klabunde CN, Fletcher RH, Rogers SO, Doucette WR, Tisnado D, Clauser S, Kahn KL.

J Clin Oncol. 2008 May 20;26(15):2532-7. doi: 10.1200/JCO.2007.15.9434.

PMID:
18487570
7.

Breast cancer treatment guidelines in older women.

Giordano SH, Hortobagyi GN, Kau SW, Theriault RL, Bondy ML.

J Clin Oncol. 2005 Feb 1;23(4):783-91.

PMID:
15681522
8.

NCCN Task Force Report: Adjuvant Therapy for Breast Cancer.

Carlson RW, Brown E, Burstein HJ, Gradishar WJ, Hudis CA, Loprinzi C, Mamounas EP, Perez EA, Pritchard K, Ravdin P, Recht A, Somlo G, Theriault RL, Winer EP, Wolff AC; National Comprehensive Cancer Network..

J Natl Compr Canc Netw. 2006 Mar;4 Suppl 1:S1-26. Review.

PMID:
16507275
9.

How important is the axillary nodal status for adjuvant treatment decisions at a breast cancer multidisciplinary tumor board? A survival analysis.

Reimer T, Fietkau R, Markmann S, Stachs A, Gerber B.

Ann Surg Oncol. 2008 Feb;15(2):472-7. Epub 2007 Nov 7.

PMID:
17987339
10.

Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.

Johansson P, Fohlin H, Arnesson LG, Dufmats M, Nordenskjöld K, Nordenskjöld B, Stål O; South-East Sweden Breast Cancer Study Group..

Acta Oncol. 2009;48(4):504-13. doi: 10.1080/02841860902718754.

PMID:
19235568
11.

Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.

Søiland H, Skaland I, Varhaug JE, Kørner H, Janssen EA, Gudlaugsson E, Baak JP, Søreide JA.

Acta Oncol. 2009;48(4):514-21. doi: 10.1080/02841860802620613.

PMID:
19107621
12.

Accuracy validation of adjuvant! online in Taiwanese breast cancer patients--a 10-year analysis.

Yao-Lung K, Dar-Ren C, Tsai-Wang C.

BMC Med Inform Decis Mak. 2012 Sep 17;12:108. doi: 10.1186/1472-6947-12-108.

13.

DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy.

Hartmann O, Spyratos F, Harbeck N, Dietrich D, Fassbender A, Schmitt M, Eppenberger-Castori S, Vuaroqueaux V, Lerebours F, Welzel K, Maier S, Plum A, Niemann S, Foekens JA, Lesche R, Martens JW.

Clin Cancer Res. 2009 Jan 1;15(1):315-23. doi: 10.1158/1078-0432.CCR-08-0166.

14.

MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status.

Bathen TF, Jensen LR, Sitter B, Fjösne HE, Halgunset J, Axelson DE, Gribbestad IS, Lundgren S.

Breast Cancer Res Treat. 2007 Aug;104(2):181-9. Epub 2006 Oct 24.

PMID:
17061040
15.

Retrospective study of the effect of comorbidity on use of adjuvant chemotherapy in older women with breast cancer in a tertiary care setting.

Hawfield A, Lovato J, Covington D, Kimmick G.

Crit Rev Oncol Hematol. 2006 Sep;59(3):250-5. Epub 2006 Mar 9.

PMID:
16527489
16.
17.

Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Online risk categories in early breast cancer.

Jung SY, Han W, Lee JW, Ko E, Kim E, Yu JH, Moon HG, Park IA, Oh DY, Im SA, Kim TY, Hwang KT, Kim SW, Noh DY.

Ann Surg Oncol. 2009 May;16(5):1112-21. doi: 10.1245/s10434-009-0334-7. Epub 2009 Feb 14.

PMID:
19219507
18.

A prediction model for breast cancer recurrence after adjuvant hormone therapy.

Boracchi P, Coradini D, Antolini S, Oriana S, Dittadi R, Gion M, Daidone MG, Biganzoli E.

Int J Biol Markers. 2008 Oct-Dec;23(4):199-206.

PMID:
19199266
19.

A stochastic simulation model of U.S. breast cancer mortality trends from 1975 to 2000.

Plevritis SK, Sigal BM, Salzman P, Rosenberg J, Glynn P.

J Natl Cancer Inst Monogr. 2006;(36):86-95.

PMID:
17032898
20.

A computer program to assist in making breast cancer adjuvant therapy decisions.

Ravdin PM.

Semin Oncol. 1996 Feb;23(1 Suppl 2):43-50.

PMID:
8614844

Supplemental Content

Support Center